Clinical trials: Change; Mental
Schizophrenia
Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"
The aim of this study is observation, in an Italian real-world setting, of metabolic effects in patients with schizophrenia who will switch from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with…
- Trial name
- SWITCH (NCT04312503)
- Testing
- Lurasidone, aripiprazole, olanzapine, quetiapine or risperidone
- Where
- 18 sites in Italy
- Volunteers
- 95 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Menopause, Menopausal Symptoms
A Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being
This study evaluates the effects of Primal Harvest's Primal Meno+ supplement on symptoms of menopause and overall well-being in females aged 40-60 who are currently menopausal and experiencing at least two menopausal symptoms.
- Conditions
- Menopause, Menopausal Symptoms, Hot Flashes, Night Sweats
- Trial name
- NCT07903480
- Testing
- Primal Meno+ Supplement
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Primal Harvest, LLC
Alzheimer's Disease (AD)
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and…
- Trial name
- NCT02681172
- Testing
- Neuraceq (florbetaben 18F), PET
- Where
- France
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue
A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.
This is a single-group, open-label, uncontrolled clinical trial designed to evaluate the effects of Adrenal Adapt, a commercially available dietary supplement, on sleep quality, daytime energy, stress resilience, and cognitive…
- Conditions
- Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue, Improves Overall Sleep Quality and Restorative Sleep, Helps People Fall Asleep Faster and Wake Less During the Night
- Trial name
- NCT07893561
- Testing
- Adrenal Adapt
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bioligent
Mild Cognitive Impairment, Metabolic Syndrome
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts…
- Trial name
- NCT03319173
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Alzheimer's Disease (AD)
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- Abroad (NCT05771428)
- Testing
- ABBV-552
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 263 people
- Sponsor
- AbbVie
Sleep Apnea, Sleep Apnea, Obstructive
Proof-of-Concept Study to Determine the Flow Changes When Stimulating Two Neural Targets for the Treatment of Obstructive Sleep Apnea
This proof-of-concept study will evaluate the impact of surgically placing and stimulating the hypoglossal nerve and/or a second neural target Ansa Cervicalis, with a set of off-the-shelf electrode arrays.
- Conditions
- Sleep Apnea, Sleep Apnea, Obstructive, Sleep Disorder, Sleep Apnea Syndromes
- Trial name
- NCT06415981
- Testing
- Hypoglossal nerve and/or Ansa Cervicalis stimulation
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Invicta Medical Inc.
Alzheimer's Disease
Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
This study used two doses of rivastigmine transdermal patch (5 cm^2, 10 cm^2) to establish the feasibility of 2 switch schedules (with transdermal patch one-step dose titration or without dose titration) from rivastigmine…
- Trial name
- KAPA (NCT00549601)
- Testing
- Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day), Rivastigmine patch (9.5 mg/day), Rivastigmine capsules (6 mg to 12 mg/day)
- Where
- Spain
- Volunteers
- 142 people
- Sponsor
- Novartis
Healthy
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses
The purpose of this study is to assess safety, tolerability and pharmacokinetics of AZD1446 in young and elderly healthy Japanese volunteers.
- Trial name
- NCT01199315
- Testing
- AZD1446
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder
Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder
This study is to compare the pharmacokinetics of FK949E low dose tablets and FK949E high dose tablets in non-elderly patients with major depressive disorder. The safety of FK949E in the population was also evaluated.
- Trial name
- NCT01919008
- Testing
- FK949E
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Inc
Alzheimer Disease
Drug Interaction Study With a Potential Alzheimer's Disease Compound
The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and dextromethorphan
- Trial name
- NCT00726726
- Testing
- Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
PTSD
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT04030169
- Testing
- Midomafetamine HCl
- Where
- 6 sites in Czechia, Germany and 3 more
- Volunteers
- 21 people
- Sponsor
- MAPS Europe B.V.
Parkinson's Disease (PD)
Observational Study Evaluating Robotic Spinal Mobilization in 16 Parkinson's Disease Participants. The Study Recorded Changes in Mobility, Sit-to-stand Performance, and Pain Scores After a 2-week Intervention With the BackHug Device.
The goal of this completed observational pilot study was to evaluate the immediate and short-term clinical effects of robotic spinal mobilization on motor and non-motor symptoms in community-dwelling adults with Parkinson's…
- Trial name
- NCT07384364
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Pacla Medical Limited
Impulse Control Disorder
Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa
The purpose of this study is to see whether the ICDs(Impulse Control Disorder) are improved and neuropsychiatric traits related to ICD are changed or not when switching dopamine agonist to levodopa/carbidopa in patients with…
- Trial name
- REIN-PD (NCT01683253)
- Testing
- Levodopa/Carbidopa(200mg/50mg), Dopaminergic Agonists
- Where
- 5 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Sandoz
Alzheimer Disease
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due…
- Trial name
- NCT03901105
- Testing
- flortaucipir F18, Brain PET Scan
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- Avid Radiopharmaceuticals
Altered Mental Status, Sepsis
Pre-hospital Ventilation Clinical Study
This study will collect and characterize ventilator use during patient care with a ZOLL 731 Series ventilator in a pre-hospital setting.
- Conditions
- Altered Mental Status, Sepsis, Heart Failure, Hemorrhage
- Trial name
- NCT05604430
- Testing
- 731 Series Ventilator
- Where
- 5 sites in United States
- Volunteers
- 500 people
- Sponsor
- Zoll Medical Corporation
Sleep Initiation and Maintenance Disorders, Primary Insomnia
A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients
The purpose of the study is to investigate the efficacy and safety of zolpidem modified release (MR) tablet using estazolam (Eurodin) as a comparative drug in patients with primary insomnia.
- Trial name
- NCT00956319
- Testing
- Zolpidem MR, Estazolam
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia
Pharmacokinetic Study of MIN-101 in Healthy Subjects
The aim of the study is to assess how MIN-101 is taken up by the body when given in different amounts and in different formulations.
- Trial name
- NCT02232529
- Testing
- MIN-101
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Minerva Neurosciences
Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
The objectives of the study are to; (1) estimate the change in disease -related cognitive decline over 1 year on a battery of cognitive tests administered to participants with early-stage symptomatic Behavioral Variant…
- Trial name
- FORWARD (NCT03088956)
- Testing
- Assessments
- Where
- 12 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Biogen
Alzheimer Disease
A Study of LY3439539 in Participants With Alzheimer's Disease
The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease.
- Trial name
- NCT07598370
- Testing
- LY3439539
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company